Professional: Founder of Genomas, a biotechnology start up; co-founder, former chief executive and former chief scientific officer of Genaissance Pharmaceuticals Inc. in New Haven; former chief ...

Dr. Gualberto Ruano, co-founder and chief scientific officer at Genaissance Pharmaceuticals Inc. in New Haven, has resigned and will leave the company Aug. 31, the company announced Tuesday. Company ...

Patients at the Institute of Living at Hartford Hospital in Hartford, Conn., can now get a DNA test that can predict whether they are at risk for side effects from antidepressants and whether a drug ...

HARTFORD, Conn. and WASHINGTON, Feb. 12 /PRNewswire/ -- Gualberto Ruano, M.D., Ph.D., was inducted into the American Institute for Medical and Biological Engineering's (AIMBE) College of Fellows today ...

One-third of patients suffering from schizophrenia develop diabetes as a direct result of treatment, say experts. As a result, in 2003 the Food and Drug Administration asked all manufacturers of ...

A recent review in the Journal of the American Medical Association concluded that genomic medicine should be part of the risk assessment and treatment of common chronic diseases, yet knowledge about ...

Ruano recently left Genaissance Pharmaceuticals in New Haven, which he founded in 1997. He said his new enterprise will take genomics into the field of disease prevention and health enhancement. "We ...

Gualberto Ruaño is the president and CEO of Genomas.

The University of Connecticut’s Young Innovators Initiative Program (YIIP) is currently accepting applications until March 30. The research-intensive program supports graduate students interested in ...